Does the media favor KRYS or SLS?

In the previous week, Krystal Biotech had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Krystal Biotech and 5 mentions for SELLAS Life Sciences Group. Krystal Biotech's average media sentiment score of 1.32 beat SELLAS Life Sciences Group's score of 0.82 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ABVX or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A

Is ABVX or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% SELLAS Life Sciences Group N/A -35.91% -33.34%

Does the media favor ABVX or SLS?

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Abivax. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat SELLAS Life Sciences Group's score of 0.82 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SLS or PRAX?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A Praxis Precision Medicines N/A N/A -$303.27M -$12.93 N/A

Is SLS or PRAX more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -35.91% -33.34% Praxis Precision Medicines N/A -34.15% -32.42%

Does the media refer more to SLS or KYMR?

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat SELLAS Life Sciences Group's score of 0.82 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLS or IONS?

In the previous week, Ionis Pharmaceuticals had 22 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 5 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Ionis Pharmaceuticals' score of 0.34 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

SELLAS Life Sciences Group (SLS) Competitors

$11.55 -1.94 (-14.38%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.54 -0.02 (-0.13%)

As of 09/11/2026 07:59 PM Eastern

Compare

SLS vs. KRYS, ABVX, PRAX, KYMR, and IONS

Should you buy SELLAS Life Sciences Group stock or one of its competitors? SELLAS Life Sciences Group's main competitors and comparable companies include Krystal Biotech (KRYS), Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Krystal Biotech has a net margin of 54.82% compared to SELLAS Life Sciences Group's net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

Krystal Biotech has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

In the previous week, Krystal Biotech had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Krystal Biotech and 5 mentions for SELLAS Life Sciences Group. Krystal Biotech's average media sentiment score of 1.32 beat SELLAS Life Sciences Group's score of 0.82 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech presently has a consensus price target of $365.40, suggesting a potential upside of 5.30%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 13.42%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Krystal Biotech is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Krystal Biotech beats SELLAS Life Sciences Group on 15 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Abivax?

Abivax (NASDAQ:ABVX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Abivax presently has a consensus target price of $156.38, suggesting a potential upside of 31.81%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential downside of 13.42%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Abivax. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat SELLAS Life Sciences Group's score of 0.82 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

Abivax has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

SELLAS Life Sciences Group's return on equity of -35.91% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

47.9% of Abivax shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Abivax and SELLAS Life Sciences Group tied by winning 7 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

SELLAS Life Sciences Group (NASDAQ:SLS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential downside of 13.42%. Praxis Precision Medicines has a consensus price target of $585.95, indicating a potential upside of 75.13%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95

SELLAS Life Sciences Group has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market.

Praxis Precision Medicines' return on equity of -34.15% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 5 mentions for SELLAS Life Sciences Group. Praxis Precision Medicines' average media sentiment score of 1.41 beat SELLAS Life Sciences Group's score of 0.82 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Praxis Precision Medicines beats SELLAS Life Sciences Group on 12 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat SELLAS Life Sciences Group's score of 0.82 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 13.42%. Kymera Therapeutics has a consensus target price of $130.83, indicating a potential upside of 13.81%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88

SELLAS Life Sciences Group has higher earnings, but lower revenue than Kymera Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Kymera Therapeutics	$105M	91.04	-$311.35M	-$3.24	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

SELLAS Life Sciences Group has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Kymera Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Ionis Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Ionis Pharmaceuticals. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. SELLAS Life Sciences Group's return on equity of -35.91% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

SELLAS Life Sciences Group presently has a consensus price target of $10.00, indicating a potential downside of 13.42%. Ionis Pharmaceuticals has a consensus price target of $91.25, indicating a potential upside of 68.33%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 22 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 5 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.82 beat Ionis Pharmaceuticals' score of 0.34 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

Ionis Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.72B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-55.00	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	25.11	15.12	10.33	6.20
Net Income	-$26.86M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-16.67%	-4.34%	-3.32%	-2.35%
1 Month Performance	-1.87%	-0.02%	-0.41%	-2.77%
1 Year Performance	524.32%	40.64%	19.21%	7.63%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	0.3931 of 5 stars	$11.55 -14.4%	$10.00 -13.4%	+511.1%	$2.72B	N/A	N/A	13	High Trading Volume
KRYS Krystal Biotech	3.1574 of 5 stars	$358.24 flat	$365.40 +2.0%	+140.4%	$10.60B	$389.13M	44.89	210	Positive News
ABVX Abivax	2.6108 of 5 stars	$114.79 flat	$156.50 +36.3%	+38.0%	$10.02B	N/A	N/A	61	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.0013 of 5 stars	$351.81 flat	$585.95 +66.6%	+748.8%	$9.82B	$8.55M	N/A	110	News Coverage Positive News
KYMR Kymera Therapeutics	1.8089 of 5 stars	$117.39 flat	$128.70 +9.6%	+148.8%	$9.76B	$39.21M	N/A	170	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. KRYS, ABVX, PRAX, KYMR, and IONS

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Summary

How does SELLAS Life Sciences Group compare to Abivax?

Summary

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. KRYS, ABVX, PRAX, KYMR, and IONS

How does SELLAS Life Sciences Group compare to Krystal Biotech?

Is KRYS or SLS more profitable?

Which has higher valuation & earnings, KRYS or SLS?

Do institutionals and insiders hold more shares of KRYS or SLS?

Which has more volatility & risk, KRYS or SLS?

Does the media favor KRYS or SLS?

Do analysts rate KRYS or SLS?

Summary

How does SELLAS Life Sciences Group compare to Abivax?

Do analysts rate ABVX or SLS?

Does the media favor ABVX or SLS?

Which has stronger earnings & valuation, ABVX or SLS?

Which has more volatility and risk, ABVX or SLS?

Is ABVX or SLS more profitable?

Do institutionals & insiders have more ownership in ABVX or SLS?

Summary

How does SELLAS Life Sciences Group compare to Praxis Precision Medicines?

Do analysts recommend SLS or PRAX?

Which has more volatility & risk, SLS or PRAX?

Is SLS or PRAX more profitable?

Which has preferable valuation & earnings, SLS or PRAX?

Do institutionals and insiders believe in SLS or PRAX?

Does the media prefer SLS or PRAX?

Summary

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Does the media refer more to SLS or KYMR?

Do analysts recommend SLS or KYMR?

Which has stronger earnings and valuation, SLS or KYMR?

Is SLS or KYMR more profitable?

Which has more risk & volatility, SLS or KYMR?

Do institutionals and insiders believe in SLS or KYMR?

Summary

How does SELLAS Life Sciences Group compare to Ionis Pharmaceuticals?

Which has better valuation and earnings, SLS or IONS?

Is SLS or IONS more profitable?

Do analysts recommend SLS or IONS?

Do insiders and institutionals believe in SLS or IONS?

Does the media refer more to SLS or IONS?

Which has more volatility & risk, SLS or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools